Molecular Subtype
HER2-Positive Gastric Adenocarcinoma
CI-CAN-00007796Explore in graph →
15 active trials
- NCIt
- C227256
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00007796Explore in graph →
Clinical trials
43 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06253650 | Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease(TRINITY) | recruiting | Phase 2 | 46 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06730373 | First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) | recruiting | Phase 2 | 110 | Qilu Hospital of Shandong UniversityOTHER | 1 | Sep 15, 2026 |
| clinicaltrials |
| NCT06764875 | A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | recruiting | Phase 3 | 840 | AstraZenecaINDUSTRY | 28 | Sep 11, 2026 | clinicaltrials |
| NCT05715931 | Perioperative Chemotherapy Plus Trastuzumab Plus Toripalimab in HER2 Positive Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma | active not recruiting | Phase 2 | 30 | Yu jirenOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT07780968 | Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA(ZOLA) | not yet recruiting | — | 300 | Jazz PharmaceuticalsINDUSTRY | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06846996 | Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China(RECOVER) | recruiting | — | 260 | Daiichi SankyoINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07685704 | Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study | not yet recruiting | Phase 2 | 46 | Zhifeng Zhao, PhDOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05514717 | A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | terminated | Phase 1 | 57 | Day One Biopharmaceuticals, Inc.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05955833 | 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study(HER Image) | completed | N/A | 6 | Amsterdam UMC, location VUmcOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT06532006 | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | recruiting | Phase 3 | 550 | Shanghai Henlius BiotechINDUSTRY | 17 | Feb 27, 2026 | clinicaltrials |
| NCT07332533 | A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer | not yet recruiting | Phase 2 / Phase 3 | 490 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | Jan 12, 2026 | clinicaltrials |
| NCT07334431 | Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer | recruiting | Phase 1 / Phase 2 | 45 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 12, 2026 | clinicaltrials |
| NCT06328738 | ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | active not recruiting | Phase 1 | 275 | Enliven TherapeuticsINDUSTRY | 7 | Nov 19, 2025 | clinicaltrials |
| NCT04082364 | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer(MAHOGANY) | completed | Phase 2 / Phase 3 | 82 | MacroGenicsINDUSTRY | 9 | Jun 8, 2025 | clinicaltrials |
| NCT04727151 | TAC T-cells for the Treatment of HER2-positive Solid Tumors(TACTIC-2) | terminated | Phase 1 / Phase 2 | 28 | Triumvira Immunologics, Inc.INDUSTRY | 2 | Jun 8, 2025 | clinicaltrials |
| NCT06998771 | JSKN003 Combined Treatment of HER2-positive Gastric Cancer | not yet recruiting | Phase 2 | 153 | Shanghai JMT-Bio Inc.INDUSTRY | 0 | May 31, 2025 | clinicaltrials |
| NCT05586061 | First-line Treatment with RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer(RCTS) | active not recruiting | Phase 2 | 55 | Qilu Hospital of Shandong UniversityOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT05555251 | BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors(CONTRAST) | terminated | Phase 1 / Phase 2 | 18 | BioInvent International ABINDUSTRY | 3 | Dec 16, 2024 | clinicaltrials |
| NCT04319757 | ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | completed | Phase 1 | 12 | Acepodia Biotech, Inc.INDUSTRY | 2 | Dec 5, 2024 | clinicaltrials |
| NCT06572319 | Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens | recruiting | Phase 1 / Phase 2 | 35 | Zhejiang Cancer HospitalOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06492317 | RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer | not yet recruiting | Phase 2 | 20 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06439550 | Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC | not yet recruiting | Phase 2 | 42 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Jun 3, 2024 | clinicaltrials |
| NCT03330561 | PRS-343 in HER2-Positive Solid Tumors | completed | Phase 1 | 85 | Pieris Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03650348 | PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors | completed | Phase 1 | 41 | Pieris Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | withdrawn | Phase 1 | 0 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT05982834 | Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC | unknown | Phase 1 / Phase 2 | 43 | Fudan UniversityOTHER | 1 | Aug 9, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04650451 | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors | suspended | Phase 1 | 220 | Bellicum PharmaceuticalsINDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
| NCT05619016 | [68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors | unknown | Phase 2 | 72 | Karolinska University HospitalOTHER | 1 | Nov 30, 2022 | clinicaltrials |
| NCT05190445 | Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma | active not recruiting | Phase 2 | 80 | Pieris Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 8, 2022 | clinicaltrials |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers | terminated | Phase 1 / Phase 2 | 2 | Silverback TherapeuticsINDUSTRY | 1 | Aug 18, 2022 | clinicaltrials |
| NCT03409848 | Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma(INTEGA) | completed | Phase 2 | 97 | AIO-Studien-gGmbHOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT05313906 | RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05311189 | Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 0 | Apr 5, 2022 | clinicaltrials |
| NCT05270889 | Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial | unknown | Phase 2 | 50 | Yonsei UniversityOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT05165602 | Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System | unknown | — | 30 | Peking UniversityOTHER | 1 | Dec 21, 2021 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT05070598 | Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer | unknown | Phase 2 | 35 | Shengjing HospitalOTHER | 1 | Oct 7, 2021 | clinicaltrials |
| NCT04920747 | Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients(TandHER) | completed | — | 65 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jun 10, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT04520295 | ctDNA Screening in Advanced HER2 Positive Gastric Cancer | unknown | — | 100 | Ruijin HospitalOTHER | 1 | Aug 20, 2020 | clinicaltrials |
| NCT02378389 | Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer | unknown | Phase 1 | 28 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 4, 2015 | clinicaltrials |
Data updated 5 days agoSource updated Sep 23, 2026source: clinicaltrials